Chief Financial Officer
Leo Toole joined Sigmoid in October 2015 with an impressive track record in both private and public companies inmedtech and consumer goods sectors. Since 2011, he has been Finance Director at ResMed Inc. reporting to the Chief Financial Officer. Prior to that, as Chief Financial Officer at BiancaMed, where he was instrumental in fundraising, establishing and growing a robust finance function, and securing a major liquidity event through tradesale to ResMed. Leo spent nearly 10 years in finance with Procter & Gamble, the world’s leading consumer goods company. Leo graduated with Distinction from INSEAD and completed his undergraduate studies in Trinity College Dublin and HEC Liege
SmPill® is the main focus of Sigmoid’s current development work and underpins all product development programmes. CyCol®, Sigmoid’s lead clinical development program, which is advancing into Phase 3 trials for moderate to severe ulcerative colitis, was uniquely enabled using SmPill® drug delivery technology.